modelC10AX11

Diagram of C10AX11

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:Mipomersen
ATC code:C10AX11
route:subcutaneous
compartments:2
dosage:200mg
volume of distribution:6.1L
clearance:5.3mL/h/kg
other parameters in model implementation

Mipomersen is an antisense oligonucleotide inhibitor of apolipoprotein B-100 synthesis, used for the treatment of homozygous familial hypercholesterolemia to reduce LDL cholesterol. It was approved by the FDA but is not currently marketed in many regions, including the US, due to safety concerns.

Pharmacokinetics

Pharmacokinetic parameters reported in adult patients with homozygous familial hypercholesterolemia after subcutaneous administration.

References

  1. Patel, N, & Hegele, RA (2010). Mipomersen as a potential adjunctive therapy for hypercholesterolemia. Expert opinion on pharmacotherapy 11(15) 2569–2572. DOI:10.1517/14656566.2010.512006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20707601

  2. Li, Z, et al., & von Moltke, LL (2014). Pharmacokinetics, safety and tolerability of mipomersen in healthy Japanese volunteers and comparison with Western subjects. International journal of clinical pharmacology and therapeutics 52(4) 314–320. DOI:10.5414/CP201975 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24548981

  3. Li, Z, et al., & Boltje, I (2014). Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersen. Journal of cardiovascular pharmacology 64(2) 164–171. DOI:10.1097/FJC.0000000000000101 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24691275

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)